Jun 15 marks World Dengue Day, a reminder of the fight against a disease that continues to impact millions, particularly in Southeast Asia. In Indonesia, authorities are pressing on with a promising ...

India bears one-third of global dengue cases, with climate change, urbanization, and poor sanitation fueling its spread. The EquiHealth Alliance calls for an equity-driven, multi-sector dengue ...

The death has been reported in the Dhaka South City Corporation, according to the Directorate General of Health Services (DGHS) ...

Scorching heat persisted in the city on Saturday as temperatures soared to 44°C, under sunny to partly cloudy skies. The Pakistan Meteorological Department has issued a warning that strong windstorms, ...

The event contributed to promoting multi-sectoral dialogue and enhancing public awareness, in the context that the World Health Organization (WHO) has identified dengue as one of the top 10 global ...

According to the Directorate General of Health Services (DGHS), in recent fatalities, one was reported in Chattogram Division ...

Punjab health minister Dr Balbir Singh emphasised that the health department is educating the public on preventive measures to mitigate the risks of vector-borne diseases and weather-related health co ...

Five more deaths were reported from dengue in 24 hours till Friday morning (13 June) – the highest number of deaths in a single day so far this year, raising the number of fatalities from the Aedes ...

They will be randomised and given either a single dose of the vaccine or a placebo. More than 30 trial sites across dengue ...

Five deaths were reported from dengue in 24 hour till Friday morning, raising the number of fatalities from the mosquito-borne disease in Bangladesh 28 this year.

"During the period, 89 were hospitalised in Barishal, four in Chattogram, one in Rajshahi, three in Dhaka division, one in Dhaka north and 10 were admitted to different hospitals in Dhaka south," said ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a ...